Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
about
Antifungal susceptibility testing: practical aspects and current challenges.Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasisItraconazole--perspectives for the management of invasive aspergillosis.Changing strategies for the management of invasive fungal infections.Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsSingle-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.Pharmacokinetics of antifungal agents in children.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.Antifungal prophylaxis following reduced-intensity stem cell transplantation.Antimicrobial dosing in acute renal replacement.Pediatric antifungal agents.Pharmacology and clinical use of voriconazole.Invasive fungal infections in the ICU.Caspofungin therapy in immunocompromised children and neonates.In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.Novel, Synergistic Antifungal Combinations that Target Translation Fidelity.Advances in synthetic approach to and antifungal activity of triazoles.
P2860
Q33975757-E4426616-AC12-4021-BFAA-76D7A3F0506FQ34111158-CD76CDC8-084A-4074-873E-68D0DDBE8FB8Q35105394-47BE84C1-46D9-40F4-9031-6ECE9E9E753DQ35678997-87581D47-FA12-42F0-B9A2-A876EFF27BE6Q35685548-5CFCCE8B-E9E7-42D7-BF68-8DB200E8B337Q35912756-D24E469D-9B9A-483A-99D4-52E1C5E39227Q36163345-FCD022A3-313B-4B21-A149-B046659F44A4Q36482785-2FB20F98-AB0F-493A-994A-2DF8CDE0BF27Q36658236-98B43B40-0D06-4B30-8439-C97BD07B1ADDQ37252494-315D1637-2EF9-4676-AC37-6A180E00E672Q37594515-6155F0A2-71E4-45B5-9C50-BFCFED01161EQ37641375-4EFF5C56-A56A-426D-B5B8-13E90B009C95Q37643057-297D8E92-96DF-4640-A9E5-FDF37959127AQ37854725-79179A86-3040-402F-A68B-7535312C2DD2Q39731811-3CF50299-3C80-4C59-A408-0D58C5A5F589Q42059863-7C4768B2-F970-4FB3-AA03-90F7572DCEAFQ42206400-63050577-043B-47B2-86DE-9E34F99B443F
P2860
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@ast
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@en
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@nl
type
label
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@ast
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@en
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@nl
prefLabel
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@ast
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@en
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@nl
P2093
P2860
P1433
P1476
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.
@en
P2093
P2860
P304
P356
10.1592/PHCO.21.12.133S.34507
P407
P433
P577
2001-08-01T00:00:00Z